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AND COST-EFFECTIVENESS OF MASS VACCINATION USING LIVE 
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OBJECTIVES: 1) To estimate the public health impact of mass vaccination using Live 
Attenuated Human Rotavirus Vaccine (LA-HRV) in a developing Asian country; 2)
to estimate the incremental cost-effectiveness of such a program. METHODS: We 
developed an individual-based time-dependent Markov model in which infection 
probability and severity depended on age, prior infection history, and vaccination 
history; and in which utilization probabilities depended on symptom severity. Over a
ﬁ ve year horizon, we examined a hypothetical birth cohort in India, our representation 
of a developing Asian country. Parameter estimates were based on published clinical, 
epidemiological, and economic data. Vaccine efﬁ cacy was adjusted for regional strain
distributions. Outcome measures were change in the numbers of rotavirus episodes
(non-severe and severe), deaths, outpatient visits, and hospitalizations; incremental 
cost-effectiveness ratio (ICER) of vaccination expressed as 2007 Rupees (Rs) / life year
saved (LYS). RESULTS: LA-HRV vaccination would be expected to prevent 28,872 
(29.6%) rotavirus gastroenteritis episodes, 3,104 (36.1%) severe episodes, 151 deaths
(36.3%), 5,395 (31.0%) outpatient visits, and 483 (32.5%) hospitalizations per 
100,000 children. With an ICER of Rs 14,363 (~US$ 353) / LYS, vaccination would 
be “very cost-effective” by WHO standards. Total net cost for the program would
equal roughly 11% of India’s 2006–2007 Department of Health and Family Welfare 
budget. The most inﬂ uential parameter in sensitivity analysis was that representing
access to outpatient care for the severely symptomatic, but increasing this parameter
25% did not raise the ICER above the “cost-effective” level of 3x per capita GDP. 
Probabilistic sensitivity analysis showed a 95.4% probability that vaccination would 
be cost-effective. CONCLUSIONS: Mass LA-HRV vaccination in India, our represen-
tation of a developing Asian country, would likely prevent substantial morbidity, 
mortality, and utilization across a wide range of assumptions at a cost per LYS below
standard cost-effectiveness thresholds. Nonetheless, total net vaccination cost would
be considerable.
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OBJECTIVES: To evaluate in Canada, the projected health outcomes, costs, and cost-
effectiveness of routine vaccination with the new 10-valent pneumococcal non-
typeable Haemophilus inﬂ uenzae protein-D conjugate vaccine (PHiD-CV) compared
with no vaccination and with the currently available 7-valent pneumococcal conjugate 
vaccine (PCV-7). METHODS: We used an innovative static, deterministic, age-
compartmental, and steady-state population model to simulate vaccine effects for one 
year. The model was calibrated with Canadian demographic and epidemiology 
data. The base-case analysis was performed to estimate the effects of four dose (3 
1) vaccination, assuming herd protection and pneumococcal serotype cross-protection 
(serotype 6A). Model outputs include clinical endpoints (invasive pneumococcal
disease, pneumonia, otitis media and myringotomy with ventilation tube insertion),
and economic measures (net costs per case/death prevented, life-year gained, quality-
adjusted life year gained, and disability-adjusted life-year gained). Incremental 
cost-effectiveness ratios (ICERs) were calculated comparing vaccination with no vac-
cination from the health care system perspective. Productivity loss is reported sepa-
rately and not included in the ICER. One-way and probabilistic sensitivity analyses 
were performed to evaluate the robustness of the model to variations in the underlying
parameter assumptions. RESULTS: At price-parity, annual direct and indirect costs
are $23.5M and $47.3M lower respectively for PHiD-CV compared with PCV-7.
PHiD-CV is predicted to prevent 384 additional cases of meningitis and bacteraemia 
annually compared with PCV-7. Furthermore compared with PCV-7, vaccination 
with PHiD-CV could prevent 145,308 more antibiotic prescriptions in Canada. 
The cost per QALY gained over no vaccination is $6,220 and $12,565 for PHiD-
CV and PCV-7 respectively. At price parity of $70 per dose, PHiD-CV domin-
ates PCV-7 in Canada (ICERs was $8,614 per QALY and $10,514 per LYG).
CONCLUSIONS: Based on the base-case analysis, PHiD-CV saves $70.8M in direct 
plus indirect costs versus PCV-7. At price parity PHiD-CV is a cost-saving alternative
to PCV-7.
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OBJECTIVES: This analysis aimed to: 1) identify and assess potential innovations in
measles vaccination, and 2) pilot test a methodological framework using prospective
cost-effectiveness analysis based on measles transmission mathematical modeling to 
inform global investment decisions. METHODS: Potential innovations available by 
2020 were identiﬁ ed based on the literature and interviews with experts. Two sets of 
models were constructed to explore cost-effectiveness scenarios and the sensitivity of 
results: 1) a dynamic, compartmental measles transmission model estimated for six 
developing countries, and 2) an aggregate global cost model to project the volume of 
measles vaccine use and the impact of any per dose cost savings over the period 
2010–49 in the 84 countries currently purchasing single-antigen measles vaccine. 
RESULTS: Four innovations were assessed: 1) needle-free, jet injection of the current 
vaccine; 2) aerosolized delivery of the current vaccine via nebulizer; 3) inhalable, more 
thermostable dry powder vaccine; and 4) DNA vaccine for early administration (two 
doses). For the six countries, the health outcomes impact of the new technologies on
absolute disease burden would be beneﬁ cial, but minimal compared to the conven-
tional vaccine at target coverage levels. With a projected 4.2 billion births over this
period, aggregate, global discounted cost savings—due to reduced wastage and sharps
disposal—were projected as: $98 million for jet injector, $154 million for the aerosol, 
and $689 million for the inhalable dry powder. The DNA vaccine would increase 
spending by $3.9 billion. CONCLUSIONS: Three potential measles vaccination tech-
nologies on the horizon are projected to be net cost-saving—from a global perspec-
tive—over the long-term. Although difﬁ cult to demonstrate pre-launch, developers 
expect these innovations to improve coverage and reduce disease burden. Decisions
about additional investments will require research on the costs and likelihood of 
success in development as well as the costs and barriers to uptake, including system
readiness.
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OBJECTIVES: Different model types can be used for assessing the economic value 
of new interventions but they may give different results. Our study-objective is to 
compare the economic results for pneumococcal vaccination between a cross-sectional
population model and a cohort model. If the indirect vaccine effect is large, the 
demographic composition of the population may heavily inﬂ uence the results. 
METHODS: Both cohort and population models were developed in Excel, and
adapted to the UK to evaluate the cost-effectiveness of PHiD-CV (pneumococcal 
Haemophilus inﬂ uenzae-protein D conjugate vaccine), 3  1 dosing schedule, 100% 
coverage, vs. no vaccine. The models estimate the vaccine effect on meningitis, bacte-
remia, pneumonia and otitis media. For the population model the evaluation occurs 
at vaccine steady-state condition over a one-year period across the whole UK popula-
tion, whilst for the cohort model one birth cohort is followed over lifetime. Input data
from literature, national databases and trial results were used; natural mortality was 
only included in the cohort model; the population model used the current demographic 
distribution. Costs were assessed from the UK health care perspective. Incremental
cost-effectiveness ratios (ICERs) were derived from both models and compared. Sen-
sitivity analysis was performed on demographic changes in the population model.
RESULTS: With herd protection and replacement the ICER results for the UK were
GBP6,117 per QALY gained in the cohort model and slightly higher in the population
model, GBP6,360. Decreasing the number of people in the younger age groups and 
increasing in the older age-groups by two-fold heavily impacted the population model 
ICER-results by more than 30%. CONCLUSIONS: Both the population and cohort 
model provide similar results with the current demographic composition in the UK.
However the population model may report more accurate information if the indirect 
vaccine effect is large, quickly obtained, and the demographic composition of the 
population is not homogeneous.
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OBJECTIVES: To examine the association between insurance gaps in the United
States and anti-hypertension medication adherence using a national representative
sample of working adults. METHODS: This study used 3 most recent 2-year 
panels from the Medical Expenditure Panel Survey (MEPS) (2002–03, 2003–04, and
2004–05). We identiﬁ ed hypertensive individuals who were 18 to 65 years of age based 
on the household interviews and medical provider questionnaires. Five insurance
statuses were identiﬁ ed. Bivariate probit and logit models were used to analyze the 
association between interruptions in anti-hypertension prescription drug usage and 
the insurance statuses after controlling for individual characteristics such as age, race,
gender, year of education and BMI. We conducted the analysis by concatenating the 
three panels to increase the efﬁ ciency of the estimation. RESULTS: We obtained com-
parable results from the Bivariate probit and logit models. Individuals with continuous
public insurance coverage are more likely to adhere to their medication with a mar-
ginal effect of 3% (P  0.05). Patients with multiple insurance gaps are more likely 
to interrupt their anti-hypertension medication regime with marginal effect of 4.8%
